Human Xenograft Tumor Models (Nude Mice)

Human Xenograft Tumor Models in a nude mice are used for evaluation of potential cancer therapies. Our range of Xenograft Models ensures a wide variety of testing alternatives for your agent.Subcutaneous injection of cell lines in immunocompromised mice strain results in rapid tumor growth at the site of injection.

The xenograft model offers rapid screen of anti-tumor effect of drugs in animal models. Our experienced team has established and validated a number of models in Nude and SCID mice. The team also has prior experience in developing syngeneic models. We offer customised xenograft model development to our clients. The AAALAC accredited animal facility is equipped to house immune-compromised mice in individually ventilated cage system.

Our broad range of cancer cell lines ensures a wide variety of testing alternatives for your agent. Our xenograft model portfolio is evaluated on a regular basis for response to standards of care and this data is available for designing combination studies. Our scientific staff can assist in selecting the most appropriate model for your agent.

Get in Touch With Our Scientific Team

Complete profiling of agents can be carried out in a variety of tumor types or in combination with the appropriate clinical agent.

Xenograft Efficacy Models – Chronic:*

  • Human SK-o-V3 (ovarian cancer cell line) xenograft model in female Ncr nu/nu mice
  • Human KM-12 (colon cancer cell line) xenograft model in female Ncr nu/nu mice
  • Human A-549 xenograft model in Ncr nu/nu mice: effect of paclitaxel
  • Human MDA-MB-231 (triple negative breast cancer cell line) xenograft model in SCID-beige mice
  • Human DU-145 (prostate cancer cell line) xenograft model in male Ncr nu/nu mice
  • Human U87 MG (glioblastoma) xenograft model in SCID beige mice

Syngeneic Models:*

B16F10 (melanoma) in C57BL/6 mice
B16F10 lung metastasis model in C57BL/6 mice
4T1 (metastatic breast cancer cell line) xenograft in female BALB/c mice

Sub-chronic Xenograft Models:

  • Pharmacokinetics and bioavailability of API in tumor bearing/non-tumor bearing mice
  • Target engagement of compound in tumor tissue and PK-PD correlation
  • MTD studies in immunocompromised mice

*Note: Specially requested lines can be developed if a model of interest is not among those listed above.

© 2018 | GVK Biosciences Private Limited, All Rights Reserved | Terms & Conditions

Log in with your credentials

Forgot your details?